A5078607741- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Integrated Circuits and Semiconductor Failure Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Traumatic Brain Injury and Neurovascular Disturbances
- Polyamine Metabolism and Applications
- Grief, Bereavement, and Mental Health
- Veterinary Oncology Research
- Intensive Care Unit Cognitive Disorders
- Silicon Carbide Semiconductor Technologies
- Cardiac Arrest and Resuscitation
- CNS Lymphoma Diagnosis and Treatment
- Mast cells and histamine
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Protein Degradation and Inhibitors
- Palliative Care and End-of-Life Issues
- Organ Donation and Transplantation
University of California, San Diego
2021-2024
e19504 Background: Bispecific antibodies (BsAb) are emerging as a promising class of cancer immunotherapy. Teclistamab, BsAb targeting B-cell maturation antigen (BCMA) expressed on plasma cells, received FDA approval for the treatment relapsed/refractory (R/R) multiple myeloma (MM) in 2022. Here we describe real-world experience teclistamab at single institution. Methods: We retrospectively reviewed patients with R/R MM who University California San Diego and had least 6 months follow up....
Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We describe real-world baseline characteristics, efficacy, safety, and post-relapse outcomes adult patients with R/R LBCL who received CAR at University California San Diego. A total 66 were treated tisagenlecleucel or axicabtagene ciloleucel. The median age was 59.5, 21% over 70 years old. Additionally, 20% had an Eastern Cooperative Oncology...
Background: Despite well-defined American Academy of Neurology guidelines for death by whole brain criteria (brain death), there is marked variability in national practice, which some have attributed to lack formal education. Further, communication with surrogates and families about integral declaration. As such, we developed a targeted curriculum combining didactics simulation-based education improve examination subsequent skills families. Methods: Multidisciplinary critical care fellows...
The prognostic implications of tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are poorly studied in hematologic malignancies.
e19538 Background: Plasma Cell Leukemia (PCL) is a rare, but aggressive and devastating disease for which there paucity of data regarding the efficacy safety modern therapies to guide management. Data prior use showed abysmal overall survival (OS) approximately 4-12 months. There generally agreement that novel have improved outcomes, supporting this sparse due rarity disease. As such, currently no standard care agreed upon by experts, specific approach treatment varies provider. Methods: In...
e19500 Background: Idecabtagene vicleucel (ide-cel) is a novel CAR T-cell therapy that targets B-cell maturation antigen (BCMA). This single-center retrospective study reports the real-world clinical outcomes of ide-cel in patients with relapsed/refractory multiple myeloma (RRMM) additional goal investigating host predictive factors for performance. Methods: We conducted review adult RRMM who received between 2021 and 2023 at University California San Diego Health had least six months...
Background/Objectives: Idecabtagene vicleucel (ide-cel), an anti-B-cell maturation chimeric antigen receptor T-cell therapy, represents unprecedented treatment option for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, given its limitations, including the risk of adverse effects and unclear durability efficacy, there remains a need to report real-world clinical outcomes ide-cel therapy in patients with R/R MM, as well explore host predictive factors therapy. Methods: We...